The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Some will say we picked the wrong peptide. They will say I should have used a different version, CJC-1295 without DAC, mixed with another peptide called Ipamorelin. We went with CJC-1295 with DAC instead as it has the most controlled studies. CJC-1295 with DAC has 2 controlled trials in healthy adults. Ipamorelin alone has 1 controlled trial in healthy adults, plus 1 study that failed when they tried it on bowel surgery patients.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
The mix of the two has zero controlled trials.
Clinics mix Ipamorelin with CJC-1295 no-DAC because the two together are supposed to work better. But we don’t know if that’s accurate because we don’t have trial data.
The mix of the two has zero controlled trials.
CJC-1295 with DAC has 2 controlled trials in healthy adults. Ipamorelin alone has 1 controlled trial in healthy adults, plus 1 study that failed when they tried it on bowel surgery patients.
Ipamorelin alone: 1 in healthy, 1 failed Phase 2 in bowel surgery.